Skip to Main content Skip to Navigation
Journal articles

Radioimmunoconjugates for treating cancer: recent advances and current opportunities

Abstract : Introduction: Radioimmunoconjugates have been used for 30 years to diagnose and treat cancer. For many years, the use of these therapeutic tools has been limited to haematological disorders, such as non-Hodgkin's lymphoma, given that they have only had a moderate effect on solid tumours. Areas covered: Recently, several strategies have revived the potential therapeutic application for radioimmunoconjugates. In this review, the authors review the advances in immunological engineering to develop new tools like monoclonal antibodies and their derivatives. Then, the authors summarize the development of radionuclides, the use of recombinant antibodies, pretargeting approaches, and dose fractionation techniques, providing opportunities for both therapeutic and diagnostic applications. Expert opinion: Radioimmunoconjugates used in nuclear medicine have entered a new era of development. These advances give rise to a variety of opportunities in the management of various cancers, where the radiolabelled antibodies may be particularly useful in immuno-specific phenotypic imaging e.g. companion diagnostics. Concerning therapeutic applications, radioimmunoconjugates have demonstrated their efficacy in the treatment of both haematological malignancies and solid tumours. Recent procedural developments are of great interest in optimising oncological targeted therapies. In the field of cancer theranostics, we believe that radioimmunoconjugated compounds are likely to play a large part in near future. ARTICLE HISTORY
Document type :
Journal articles
Complete list of metadatas

Cited literature [57 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01635514
Contributor : Elizabeth Bernardo <>
Submitted on : Wednesday, November 15, 2017 - 11:47:09 AM
Last modification on : Thursday, November 5, 2020 - 9:54:08 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Mickael Bourgeois, Clément Bailly, Mathieu Frindel, François Guérard, Michel Chérel, et al.. Radioimmunoconjugates for treating cancer: recent advances and current opportunities. Expert Opinion on Biological Therapy, Informa Healthcare, 2017, 17 (7), pp.813 - 819. ⟨10.1080/14712598.2017.1322577⟩. ⟨inserm-01635514⟩

Share

Metrics

Record views

166